Opus Genetics (IRD) Times Interest Earned (2011 - 2026)

Opus Genetics (IRD) posted quarterly Times Interest Earned of -$143.64 for Q1 2026, down 72.83% quarter-over-quarter from -$83.11 in Q3 2025.

Opus Genetics (IRD) Times Interest Earned (2011 - 2026) Analysis & Trends

Opus Genetics (IRD) has reported Times Interest Earned for 14 consecutive years, with -$143.64 the latest figure, recorded in Q1 2026.

In Q1 2026, Times Interest Earned changed N/A year-over-year to -$143.64; the TTM figure through Mar 2026 stood at -$215.17 (changed N/A YoY), while the FY2025 annual figure was -$0.97, changed N/A from the prior year.
Times Interest Earned eased to -$143.64 in Q1 2026 per IRD's latest filing, from -$83.11 in the prior quarter.
Across five years, Times Interest Earned topped out at -$83.11 in Q3 2025 and bottomed at -$1301.6 in Q1 2022.
Historically, Times Interest Earned has averaged -$690.71 across 3 years, with a median of -$689.07 in 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.84
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	24.64
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-0.19
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	8.18
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.01
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.61
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.82
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.08
10	Opus Genetics	298.36 Mn	209.55 Mn	-	-164.80

Download Data